teriparatide (Forteo) (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC AVAILABLE: No
PREPARATIONS: Prefilled multi-dose pen containing 600 mcg/2.4ml. Each dose is 20 mcg.
STORAGE: Teriparatide injection should be stored in the refrigerator between 2 C to 8 C (36 F to 4 F). Pens should be removed from the refrigerator only when ready to use and returned to the refrigerator right after use. Teriparatide injection should not be stored in the freezer.
DOSING: The recommended dose for all FDA approved indications is 20 mcg subcutaneously once a day. Teriparatide should be administered subcutaneously in either the thigh or stomach area. Teriparatide pens are preset to deliver 20 mcg of medicine with each injection.
The safety and effectiveness of teriparatide injection has not been studied beyond 2 years of treatment.
DRUG INTERACTIONS: Teriparatide injection should be used cautiously in patients taking digoxin (Lanoxin), a medication used to treat irregular heart rhythms. Teriparatide increases calcium in the blood and high levels of calcium may increase the risk for digoxin associated side effects. Teriparatide injection should be used cautiously with other medicines that may increase calcium in the blood.
PREGNANCY: Use of teriparatide in pregnant women has not been adequately evaluated. Due to the lack of conclusive safety data, teriparatide should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Teriparatide injection is classified as FDA pregnancy risk category C. (Adverse effects have been demonstrated in animals, but there is no adequate data in humans.)
NURSING MOTHERS: It is not known if teriparatide is excreted in breast milk. As many drugs can enter human milk and have the potential of causing harm to the nursing baby, teriparatide should only be used in nursing mothers if clearly needed.
REFERENCE: FDA Prescribing Information.
Medically Reviewed by a Doctor on 6/19/2015
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions